Press Releases
Latest News & Events
Quick Facts

Paradigm shifting immunotherapy
For complex, life-threatening indications without therapies

Advanced clinical-stage pipeline
Promising results of PhIb (sepsis) and PhIIa (GvHD) studies, initiating Sepsis Phase IIb study

Multi-billion dollar
underserved markets
Sepsis | Solid Tumors, Covid-19,
Bone-Marrow Transplantations

Short regulatory approval pathway
Specialized regulation in Europe potentially enabling post-Phase II marketing approval

Strong leadership
Previously founded and managed PROLOR Biotech, a $560M exit event; Signed partnership with Pfizer, $295 Million down payment

Cash balance
~$60 Million invested; Cash balance supporting multiple clinical milestone within 18-24 months
SEC Filings
Date | Form | Description | Download |
---|
Corporate Governance
Charter of the Audit Committee of the Board of Directors | download |
Charter of the Compensation Committee of the Board of Directors | download |
Code of Business Conduct and Ethics | download |
Disclosure Policy | download |
Employee Complaint Procedures for Accounting and Auditing Matters | download |
Insider Trading Policy | download |
Subscribe to our newsletter
Find out more
14 Einstein St. Nes-Ziona, Israel, 7403618
T +972.2.6708072 | F +972.2.6708070
info@enlivex.com